This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Treprostinil" – news · newspapers · books · scholar · JSTOR(October 2021) (Learn how and when to remove this message)
Treprostinil
Clinical data
Trade names
Remodulin, Orenitram, Tyvaso, others
AHFS/Drugs.com
Monograph
License data
US DailyMed: Treprostinil
Pregnancy category
AU: B3
Routes of administration
Subcutaneous, intravenous, inhalation, by mouth
ATC code
B01AC21 (WHO)
Legal status
Legal status
US: ℞-only[1][2][3][4]
EU: Rx-only[5]
In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability
~100%
Metabolism
Substantially metabolized by the liver
Elimination half-life
4 hours
Excretion
Urine (79% of administered dose is excreted as 4% unchanged drug and 64% as identified metabolites); feces (13%)
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.[6]
Treprostinil was approved for use in the United States in May 2002.[7]
^"Remodulin- treprostinil injection, solution; Sterile diluent for remodulin- water injection, solution". DailyMed. 9 October 2023. Retrieved 21 May 2024.
^"Orenitram- treprostinil tablet, extended release; Orenitram- treprostinil kit". DailyMed. 7 November 2023. Retrieved 21 May 2024.
^"Tyvaso- treprostinil inhalant". DailyMed. 8 December 2023. Retrieved 21 May 2024.
^"Tyvaso DPI- treprostinil inhalant; Tyvaso DPI- treprostinil kit". DailyMed. 26 January 2024. Retrieved 21 May 2024.
^Cite error: The named reference Trepulmix EPAR was invoked but never defined (see the help page).
^Torres F, Rubin LJ (January 2013). "Treprostinil for the treatment of pulmonary arterial hypertension". Expert Review of Cardiovascular Therapy. 11 (1): 13–25. doi:10.1586/erc.12.160. PMID 23259441. S2CID 29661141.
^"Drug Approval Package: Remodulin (Treprostinil Sodium) NDA #021272". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 9 April 2020.
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment...
recently found improvement in symptoms with the use of eculizumab and treprostinil. Discovered by dermatopathologist, Cynthia Magro, response to eculizumab...
specifically used to treat pulmonary hypertension include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil, tadalafil...
systemic sclerosis or scleroderma associated ILD. The inhaled vasodilator treprostinil (a synthetic prostacyclin which acts as a prostaglandin I2 analogue)...
Global Information
(what is this?) (verify)